Additionally, the secretion of chemokine ligand 2 (CCL2) by TAMs triggers the activation of the PI3K/AKT/mTOR signaling cascade in tumor cells, culminating in tamoxifen resistance within breast cancer [72]. This evidence concerns the gene MTOR and breast carcinoma.